<document>

<filing_date>
2019-02-08
</filing_date>

<publication_date>
2020-11-26
</publication_date>

<priority_date>
2018-02-08
</priority_date>

<ipc_classes>
A61P31/12,A61P35/00,C07D333/38,C07D409/04,C07D409/12,C07D413/12
</ipc_classes>

<assignee>
ENYO PHARMA
</assignee>

<inventors>
MACHIN, PETER
MELDRUM, ERIC
MALAGU, KARINE FABIENNE
WINSHIP, PAUL COLIN MICHAEL
DE CHASSEY, BENOÎT
KNIGHT, JAMIE DAVID
CHAMBERS, MARK
LANARO, ROBERTA
</inventors>

<docdb_family_id>
61283124
</docdb_family_id>

<title>
NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES
</title>

<abstract>
The present invention relates to a new class of non-fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
</abstract>

<claims>
1. 1-15. (canceled)
16. A compound of formula (I): wherein: R1 represents: a hydrogen, a 3-10 membered ring, saturated or unsaturated selected from the group consisting of an aryl, a cycloalkyl, a heterocycloalkyl, a fused arylheterocycloalkyl, a fused heteroarylcycloalkyl, a fused bicycloalkyl, and a bridged carbocyclyl, said 3-10 membered ring is optionally substituted by at least one radical selected from the group consisting of: a halogen, a (C1-C6)alkyl or a (C1-C6)alkyloxy, optionally substituted by at least one halogen, a hydroxy, a —CO—R6 or a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl, and an optionally substituted aryl, or a (C1-C6)alkyl, optionally substituted by at least one radical selected from the group consisting of: a halogen, a (C1-C6)alkyloxy optionally substituted by at least one halogen, and a 3-10 membered ring as defined above; R2 represents: a hydrogen, a halogen, a (C1-C6)alkyl optionally substituted by at least one halogen, an optionally substituted aryl, or an optionally substituted cycloalkyl; R3 represents: a 5-10 membered ring, saturated or unsaturated selected from the group consisting of: an aryl optionally fused to a heterocycloalkyl a heteroaryl, a cycloalkyl, a heterocycloalkyl, and a 5-10 membered bridged carbocyclyl or heterocyclyl, said 5-10 membered ring is optionally substituted by at least one radical selected from the group consisting of: a halogen, a (C1-C6)alkyl optionally substituted by at least one halogen, or by an optionally bridged heterocycloalkyl optionally substituted by a (C1-C6)alkyl, a —NH—(C1-C6)alkyl or a —N—((C1-C6)alkyl)2, optionally substituted by at least one radical selected from the group consisting of a heterocycloalkyl, a cycloalkyl, a hydroxyl, a thiacycloalkyl-1,1dioxide and a (C1-C6)alkyloxy, a —NH-heterocycloalkyl, a —NH-cycloalkyl, a —N((C1-C6)alkyl)-heterocycloalkyl, or a —NH((C1-C6)alkyl)-thiacycloalkyl-1,1dioxide, optionally substituted by a hydroxyl, a (C1-C6)alkyl, a (C1-C6)alkyloxy or a —CO—R6 with R6 being a hydrogen or a (C1-C6)alkyl, a hydroxy, a —CN, a —CO—R6 or a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl, a (C1-C6)alkyloxy optionally substituted by at least one radical selected from the group consisting of a halogen, a hydroxy, a (C1-C6)alkyloxy, a —NR7R8 with R7 and R8 are independently a hydrogen or a (C1-C6)alkyl, a —NHCOR9, a —NHCO2R9, with R9 being a (C1-C6)alkyl, a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl, and a heterocycle, a —NHCOR9, a —NHCO2R9, or a —SO2R9, with R9 being a (C1-C6)alkyl, and a heterocycloalkyl, a bridged heterocycloalkyl, a heterocycloalkyloxy, a cycloalkyloxy, a thiaheterocycloalkyl-1,1-dioxide or a spiroheterocycloalkyl, optionally substituted by a (C1-C6)alkyl, a (C1-C6)alkyloxy, a hydroxy, a ketone, a halogen or a (C1-C6)alkyl optionally substituted by a (C1-C6)alkyloxy, or a (C1-C6)alkyl or a (C2-C6)alkenyl, optionally substituted by a 5-10 membered ring as defined above or a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl; R4 represents —COOH; and R5 represents: a hydrogen, or a (C1-C6)alkyl optionally substituted by at least one halogen; with the proviso that when R1 is a phenyl or a phenyl substituted by a bromine, a methyl, a methoxy or an ethoxy, then R3 is not a phenyl substituted by a tert-butyl; and with the proviso that when R1 is a hydrogen, then R3 is a 5-10 membered ring and R2 is an optionally substituted aryl or an optionally substituted cycloalkyl; and the stereoisomers and the pharmaceutical salts thereof.
17. The compound according to claim 16, wherein: R1 represents: a fused arylheterocycloalkyl, a fused heteroarylcycloalkyl, a fused bicycloalkyl, a cycloalkyl or an aryl, optionally substituted by at least one radical selected from the group consisting of: a halogen, a (C1-C6)alkyl optionally substituted by at least one halogen, a (C1-C6)alkyloxy optionally substituted by at least one halogen, and an optionally substituted phenyl, a bridged carbocyclyl, or a (C1-C6)alkyl optionally substituted by at least one halogen, or optionally substituted by at least one fluorine.
18. The compound according to claim 16, wherein: R1 represents: a phenyl fused to a tetrahydropyran, or a fused bicycloalkyl, a cycloalkyl, optionally substituted by at least one radical selected from the group consisting of: a halogen, a (C1-C6)alkyl optionally substituted by at least one halogen, and an optionally substituted phenyl, an aryl, optionally substituted by at least one radical selected from the group consisting of: a halogen, a (C1-C6)alkyl optionally substituted by at least one halogen, and a (C1-C6)alkyloxy, optionally substituted by at least one halogen, a bridged carbocyclyl, or a (C1-C6)alkyl optionally substituted by at least one halogen.
19. The compound according to claim 16, wherein: R3 represents an aryl, optionally substituted by at least one radical selected from the group consisting of: a heterocycloalkyl, optionally substituted by a (C1-C6)alkyloxy, a (C1-C6)alkyloxy or a (C1-C6)alkyl optionally substituted by at least one halogen, or a (C1-C6)alkyloxy, a halogen, a —NH—(C1-C6)alkyl or a —N—((C1-C6)alkyl)2, optionally substituted by a heterocycloalkyl or a (C1-C6)alkyloxy, and a —NH-heterocycloalkyl.
20. The compound according to claim 16, wherein: R3 represents: a phenyl, optionally substituted by at least one radical selected from the group consisting of: a morpholinyl, a —NH-tetrahydropyranyl, a —NH—(C1-C6)alkyl, optionally substituted by a tetrahydropyranyl or a (C1-C6)alkyloxy, a —N—((C1-C6)alkyl)2, optionally substituted by a tetrahydropyranyl or a (C1-C6)alkyloxy, an azetidinyl optionally substituted by a (C1-C6)alkyloxy, a (C1-C6)alkyloxy, optionally substituted by at least one halogen, or a (C1-C6)alkyloxy, a halogen, and a (C1-C6)alkyl optionally substituted by at least one halogen.
21. The compound according to claim 16, wherein: R2 represents: a hydrogen, a halogen, or a (C1-C3)alkyl, and R1 represents: a phenyl fused to a tetrahydropyran, or a fused bicycloalkyl, a cycloalkyl, optionally substituted by at least one radical selected from the group consisting of: a halogen, a (C1-C6)alkyl optionally substituted by at least one halogen, and an optionally substituted phenyl, an aryl, optionally substituted by at least one radical selected from the group consisting of: a halogen, a (C1-C6)alkyl optionally substituted by at least one halogen, and a (C1-C6)alkyloxy, optionally substituted by at least one halogen, or a bridged carbocyclyl, or a bridged cyclohexyl.
22. The compound according to claim 16, wherein: R2 represents: a hydrogen, a halogen, a (C1-C6)alkyl, an optionally substituted (C3-C6)cycloalkyl, or an optionally substituted aryl; and R1 represents a hydrogen or a (C1-C6)alkyl optionally substituted by at least one halogen.
23. The compound of formula (I) according to claim 16, wherein said compound is selected from the group consisting of: 2-Benzamido-4-(4-chlorophenyl)thiophene-3-carboxylic acid (Compound #1); 2-Benzamido-4-(4-chloro-3-fluoro-phenyl)thiophene-3-carboxylic acid (Compound #2); 2-Benzamido-4-(4-chlorophenyl)-5-methyl-thiophene-3-carboxylic acid (Compound #4); 4-(4-Chlorophenyl)-2-[[4-(difluoromethoxy)benzoyl]amino]-5-methyl-thiophene-3-carboxylic acid (Compound #5); 2-Benzamido-5-chloro-4-(4-chloro-3-fluoro-phenyl)thiophene-3-carboxylic acid (compound #6); 2-Benzamido-4-norbornan-2-yl-thiophene-3-carboxylic acid (Compound #9); 2-Benzamido-4-cyclopentyl-thiophene-3-carboxylic acid (Compound #10); 4-Cyclohexyl-2-[[4-(difluoromethoxy)benzoyl]amino]thiophene-3-carboxylic acid (Compound #11); 2-Benzamido-5-chloro-4-cyclohexyl-thiophene-3-carboxylic acid (Compound #12); 5-Chloro-4-cyclohexyl-2-[[4-(difluoromethoxy)benzoyl]amino]thiophene-3-carboxylic acid (Compound #13); 5-Chloro-4-cyclohexyl-2-[(2-methylbenzoyl)amino]thiophene-3-carboxylic acid (Compound #14); 5-Chloro-4-cyclohexyl-2-[(4-morpholinobenzoyl)amino]thiophene-3-carboxylic acid (Compound #15); 2-Benzamido-5-chloro-4-cyclopentyl-thiophene-3-carboxylic acid (Compound #18); 2-Benzamido-4-[4-(trifluoromethyl)phenyl]thiophene-3-carboxylic acid (Compound #20); 2-Benzamido-4-(p-tolyl)thiophene-3-carboxylic acid (Compound #21); 2-Benzamido-4-(3,4-dimethylphenyl)thiophene-3-carboxylic acid (Compound #22); 2-Benzamido-5-chloro-4-(3,4-dimethylphenyl)thiophene-3-carboxylic acid (Compound #23); 2-Benzamido-5-chloro-4-(p-tolyl)thiophene-3-carboxylic acid (Compound #24); 4-Cyclohexyl-2-[(3,4-dimethoxybenzoyl)amino]thiophene-3-carboxylic acid (Compound #25); 2-Benzamido-4-cyclohexyl-thiophene-3-carboxylic acid (Compound #26); 2-Benzamido-4-cyclohexyl-5-methyl-thiophene-3-carboxylic acid (Compound #27); 2-[[4-(Difluoromethoxy)benzoyl]amino]-4-phenyl-thiophene-3-carboxylic acid (Compound #28); 4-Cyclohexyl-2-[(4-morpholinobenzoyl)amino]thiophene-3-carboxylic acid (Compound #29); 2-[[4-(Difluoromethoxy)benzoyl]amino]-5-methyl-4-phenyl-thiophene-3-carboxylic acid (Compound #30); 5-Chloro-2-[[4-(difluoromethoxy)benzoyl]amino]-4-phenyl-thiophene-3-carboxylic acid (Compound #31); 2-Benzamido-4-tert-butyl-thiophene-3-carboxylic acid (Compound #32); 2-Benzamido-5-chloro-4-phenyl-thiophene-3-carboxylic acid (Compound #33); 2-Benzamido-5-methyl-4-phenyl-thiophene-3-carboxylic acid (Compound #34); 2-Benzamido-4-(3,3-difluorocyclobutyl)thiophene-3-carboxylic acid (Compound #35); 2-Benzamido-4-(3-chlorophenyl)thiophene-3-carboxylic acid (Compound #36); 2-Benzamido-4-norcaran-7-yl-thiophene-3-carboxylic acid (Compound #37); 2-Benzamido-4-(4-methoxyphenyl)thiophene-3-carboxylic acid (Compound #38); 2-Benzamido-4-(2,2,3,3-tetramethylcyclopropyl)thiophene-3-carboxylic acid (Compound #39); 2-Benzamido-4-methyl-5-phenyl-thiophene-3-carboxylic acid (Compound #40); 5-Cyclohexyl-2-[[4-(difluoromethoxy)benzoyl]amino]thiophene-3-carboxylic acid (Compound #41); 2-[(2-Methylbenzoyl)amino]-4-phenyl-thiophene-3-carboxylic acid (Compound #42); 2-Benzamido-4-phenyl-thiophene-3-carboxylic acid (Compound #43); 2-Benzamido-4-(2-chlorophenyl)thiophene-3-carboxylic acid (Compound #44); 2-[(2-Methylbenzoyl)amino]-5-phenyl-thiophene-3-carboxylic acid (Compound #45); 2-[(3,4-Dimethoxybenzoyl)amino]-4-phenyl-thiophene-3-carboxylic acid (Compound #46); 2-Benzamido-4-(trans-4-tert-butylcyclohexyl)thiophene-3-carboxylic acid (Compound #48); 2-Benzamido-5-chloro-4-[4-(trifluoromethyl)phenyl]thiophene-3-carboxylic acid (Compound #50); 2-Benzamido-4-(cis-4-tert-butylcyclohexyl)thiophene-3-carboxylic acid (Compound #54); 4-Cyclopentyl-2-[(4-morpholinobenzoyl)amino]thiophene-3-carboxylic acid (Compound #59); 4-Cyclopentyl-2-[[4-(tetrahydropyran-4-ylamino)benzoyl] amino]thiophene-3-carboxylic acid (Compound #60); 4-Cyclopentyl-2-[[4-(2-methoxyethylamino)benzoyl]amino]thiophene-3-carboxylic acid (Compound #61); 4-Cyclopentyl-2-[[4-(3-methoxyazetidin-1-yl)benzoyl]amino]thiophene-3-carboxylic acid (Compound #62); 2-Benzamido-4-(3-phenylcyclobutyl)thiophene-3-carboxylic acid (Compound #63); 4-Cyclopentyl-2-[[4-(tetrahydropyran-4-ylmethylamino) benzoyl]amino]thiophene-3-carboxylic acid (Compound #66); 4-Cyclopentyl-2-[(3-morpholinobenzoyl)amino]thiophene-3-carboxylic acid (Compound #71); 2-Benzamido-4-chroman-3-yl-thiophene-3-carboxylic acid (Compound #84); 2-Benzamido-4-chroman-2-yl-thiophene-3-carboxylic acid (Compound #85); 2-Benzamido-4-cyclopropyl-thiophene-3-carboxylic acid (Compound #87); 4-Cyclopropyl-2-[[4-(3-methoxyazetidin-1-yl)benzoyl]amino]thiophene-3-carboxylic acid (Compound #88); 4-Cyclopropyl-2-[[4-(tetrahydropyran-4-ylmethylamino)benzoyl] amino]thiophene-3-carboxylic acid (Compound #90); 4-Tert-butyl-2-[[4-(tetrahydropyran-4-ylmethylamino)benzoyl]amino] thiophene-3-carboxylic acid (Compound #91); 4-tert-Butyl-2-[[4-(3-methoxyazetidin-1-yl)benzoyl]amino]thiophene-3-carboxylic acid (Compound #92); 4-Chroman-3-yl-2-[[4-(2-methoxyethoxy)benzoyl]amino]thiophene-3-carboxylic acid (Compound #95); 2-Benzamido-4-isobutyl-thiophene-3-carboxylic acid (Compound #96); 4-Cyclobutyl-2-[[4-(3-methoxyazetidin-1-yl)benzoyl]amino]thiophene-3-carboxylic acid (Compound #97); 2-Benzamido-4-cyclobutyl-thiophene-3-carboxylic acid (Compound #98); 4-Cyclobutyl-2-[[4-(tetrahydropyran-4-ylmethylamino)benzoyl] amino]thiophene-3-carboxylic acid (Compound #99); 2-[[4-(3-Methoxyazetidin-1-yl)benzoyl]amino]-4,5-dimethyl-thiophene-3-carboxylic acid (Compound #100); 4,5-Dimethyl-2-[[4-(tetrahydropyran-4-ylmethylamino)benzoyl]amino] thiophene-3-carboxylic acid (Compound #102); 4-tert-Butyl-2-[[4-(2-methoxyethylamino)benzoyl]amino]thiophene-3-carboxylic acid (Compound #103); 4-tert-Butyl-2-[[4-(3-ethoxyazetidin-1-yl)benzoyl]amino]thiophene-3-carboxylic acid (Compound #104); 4-tert-Butyl-2-[[4-(tetrahydropyran-4-ylamino)benzoyl]amino]thiophene-3-carboxylic acid (Compound #105); 4-(3,3-Difluorocyclobutyl)-2-[[4-(tetrahydropyran-4-ylmethylamino) benzoyl]amino] thiophene-3-carboxylic acid (Compound #106); 4-(3,3-Difluorocyclobutyl)-2-[[4-(3-methoxyazetidin-1-yl)benzoyl]amino]thiophene-3-carboxylic acid (Compound #107); 2-[[4-(2-Methoxyethylamino)benzoyl]amino]-4-(1-methylcyclopropyl)thiophene-3-carboxylic acid (Compound #108); 4-iso-Butyl-2-[[4-(3-methoxyazetidin-1-yl)benzoyl]amino]thiophene-3-carboxylic acid diethylamine salt (Compound #109); 4-tert-Butyl-2-[[3-(tetrahydropyran-4-ylmethylamino)benzoyl]amino]thiophene-3-carboxylic acid (Compound #110); 4-(1-Methylcyclopropyl)-2-[[4-(tetrahydropyran-4-ylmethylamino)benzoyl]amino]thiophene-3-carboxylic acid (Compound #111); 2-[[4-(3-Methoxyazetidin-1-yl)benzoyl]amino]-4-(1-methylcyclopropyl) thiophene-3-carboxylic acid (Compound #112); 4-Isobutyl-2-[[4-(tetrahydropyran-4-ylmethylamino)benzoyl]amino] thiophene-3-carboxylic acid (Compound #113); 5-Isopropyl-2-[[4-(3-methoxyazetidin-1-yl)benzoyl]amino]-4-methyl-thiophene-3-carboxylic acid diethylamine salt (Compound #114); 2-[[4-(3-Methoxyazetidin-1-yl)benzoyl]amino]-4-(1-methylcyclobutyl) thiophene-3-carboxylic acid (Compound #115); 4-tert-Butyl-2-[[4-(2-methoxyethoxy)benzoyl]amino]thiophene-3-carboxylic acid (Compound #116); 4-tert-Butyl-2-[[4-[2-methoxyethyl(methyl)amino]benzoyl] amino]thiophene-3-carboxylic acid (Compound #117); 4-tert-Butyl-2-[[4-(tetrahydropyran-3-ylamino)benzoyl]amino]thiophene-3-carboxylic acid (Compound #118); 4-tert-Butyl-2-[[4-(tetrahydropyran-3-ylmethylamino)benzoyl]amino] thiophene-3-carboxylic acid (Compound #119); 4-tert-Butyl-2-[[4-[methyl(tetrahydropyran-4-ylmethyl)amino]benzoyl] amino]thiophene-3-carboxylic acid (Compound #120); 4-tert-Butyl-2-[[2-fluoro-4-(3-methoxyazetidin-1-yl)benzoyl]amino]thiophene-3-carboxylic acid (Compound #121); and 2-Benzamido-4-(5,6,7,8-tetrahydroquinolin-2-yl)thiophene-3-carboxylic acid (Compound #195).
24. A method for treating a disease selected from the group consisting of an infection, a viral infection or a bacterial infection, a cancer, a metabolic disease, a cardiovascular disease, an inflammatory disorder, and iron storage disease or disorder comprising administering in a subject in need thereof a compound having the formula (I): wherein: R1 represents: a 3-10 membered ring, saturated or unsaturated selected from the group consisting of an aryl, a cycloalkyl, a heterocycloalkyl, a fused arylheterocycloalkyl, a fused heteroarylcycloalkyl, a fused bicycloalkyl, and a bridged carbocyclyl, said 3-10 membered ring is optionally substituted by at least one radical selected from the group consisting of: a halogen, a (C1-C6)alkyl or a (C1-C6)alkyloxy, optionally substituted by at least one halogen, and a hydroxy, a —CO—R6 or a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl, and an optionally substituted aryl, and a (C1-C6)alkyl, optionally substituted by at least one radical selected from the group consisting of: a halogen, a (C1-C6)alkyloxy optionally substituted by at least one halogen, and a 3-10 membered ring as defined above, or a hydrogen; R2 represents: a hydrogen, a halogen, a (C1-C6)alkyl optionally substituted by at least one halogen, an optionally substituted aryl, or an optionally substituted cycloalkyl; R3 represents: a 5-10 membered ring, saturated or unsaturated selected from the group consisting of: an aryl optionally fused to a heterocycloalkyl, a heteroaryl, a cycloalkyl, a heterocycloalkyl, and a 5-10 membered bridged carbocyclyl or heterocyclyl, said 5-10 membered ring is optionally substituted by at least one radical selected from the group consisting of: a halogen, a (C1-C6)alkyl optionally substituted by at least one halogen, or by an optionally bridged heterocycloalkyl optionally substituted by a (C1-C6)alkyl, a —NH—(C1-C6)alkyl or a —N—((C1-C6)alkyl)2, optionally substituted by at least one radical selected from the group consisting of a heterocycloalkyl, a cycloalkyl, a hydroxyl, a thiacycloalkyl-1,1dioxide and a (C1-C6)alkyloxy, a —NH-heterocycloalkyl, a —NH-cycloalkyl, a —N((C1-C6)alkyl)-heterocycloalkyl, or a —NH((C1-C6)alkyl)-thiacycloalkyl-1,1dioxide, optionally substituted by a hydroxyl, a (C1-C6)alkyl, a (C1-C6)alkyloxy or a —CO—R6 with R6 being a hydrogen or a (C1-C6)alkyl, a hydroxy, a —CN, a —CO—R6 or a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl, a (C1-C6)alkyloxy optionally substituted by at least one radical selected from the group consisting of a halogen, a fluorine, a hydroxy, a (C1-C6)alkyloxy, a —NR7R8 with R7 and R8 are independently a hydrogen or a (C1-C6)alkyl, a —NHCOR9, a —NHCO2R9, with R9 being a (C1-C6)alkyl, a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl, and a heterocycle, a —NHCOR9, a —NHCO2R9, or a —SO2R9, with R9 being a (C1-C6)alkyl, and a heterocycloalkyl, a bridged heterocycloalkyl, a heterocycloalkyloxy, a cycloalkyloxy, a thiaheterocycloalkyl-1,1-dioxide or a spiroheterocycloalkyl, optionally substituted by a (C1-C6)alkyl, a (C1-C6)alkyloxy, a hydroxy, a ketone, a halogen or a (C1-C6)alkyl optionally substituted by a (C1-C6)alkyloxy; or a (C1-C6)alkyl or a (C2-C6)alkenyl, optionally substituted by a 5-10 membered ring as defined above or a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl; R4 represents —COOH; and R5 represents: a hydrogen, or a (C1-C6)alkyl optionally substituted by at least one halogen, and the stereoisomers, and the pharmaceutical salts thereof.
25. The method according to claim 24, wherein said compound is selected from the group consisting of compounds of the table A.
26. The method according to claim 24, wherein the viral infection is an infection by a virus selected from the group consisting of Alphaviridae, Flaviviridae, Hepadnaviridae, Herpesviridae, Orthomyxoviridae, Papovaviridae, Paramyxoviridae, Picornaviridae, Polyomaviridae, Reoviridae, Retroviridae, Rhabdoviridae, and Tobamoviruses.
27. The method according to claim 24, wherein: the bacterial infection is an infection by a bacterium selected from the group consisting of Helicobacter pylori, Burkholderia cepacia, Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenotrophomonas maltophilia, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Francisella tularensis, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Bordetella parapertussis, Bordetella bronchiseptica, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Branhamella catarrhalis, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Borrelia burgdorferi, Vibrio cholerae, Vibrio parahaemolyticus, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Kingella denitrificans, Kingella indologenes, Kingella kingae, Kingella oralis, Legionella pneumophila, Moraxella bovis, Moraxella catarrhalis, Moraxella lacunata, Gardnerella vaginalis, Bacteroides fragilis, Bacteroides distasonis, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides unformis, Bacteroides eggerthii, Bacteroides splanchnicus, Clostridium difficile, Clostridium tetani, Mycobacterium species, Corynebacterium ulcerans, Streptococcus agalactiae, Gardnerella vaginitis, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Fusobacterium nucleatum, Porphyromonas gingivalis, Vibrio vulnificus, Clostridium botulinum, Corynebacterium diptheriae, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus saccharolyticus; the cancer is selected from the group consisting of a breast cancer, a lung cancer, NSCLC, a melanoma, a colorectal cancer, an astrocytoma cancer, a liver cancer, leukemia acute myeloid leukemia, a gastric cancer, a head and neck cancer, a cervical cancer, a pancreatic cancer, and an ovarian cancer; the metabolic disease is selected from the group consisting of Diabetes mellitus, insulin resistance, insulin deficiency, hepatic steatosis, nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis (NASH), glucose intolerance, obesity, lipodystrophy, coronary heart disease, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, hypoglycemia, hyperglycemia, beta cell dysfunction or hyperinsulinaemia, Wolfram syndrome, Wolfram syndrome from NEET proteins, Polycystic ovary syndrome, pyruvate dehydrogenase deficiency, Albright hereditary osteodystrophy, cystinosis, fructose intolerance, Walker-Warburg syndrome, hypobetalipoproteinemia, Alström syndrome, and cirrhosis; the cardiovascular disease is selected from the group consisting of myocardial injury, Ischemia, Ischemia reperfusion injury and hypertension; the inflammatory disease or disorder is selected from the group consisting of Crohn disease, inflammatory bowel disease, asthma, chronic obtrusive pulmonary disease (COPD), systemic lupus erythematosus, cystic fibrosis, psoriasis, infectious arthritis, and multiple sclerosis; and the iron storage disorder or disease is selected from the group consisting of Ferroportin Deficiency, Hereditary Hemochromatosis, including Hereditary Hemochromatosis due to HFE mutations and Hereditary Hemochromatosis due to transferrin receptor 2 mutations, Juvenile Hemochromatosis, including Juvenile Hemochromatosis due to hepcidin mutations and Juvenile Hemochromatosis due to hemojuvelin mutations, Iron Overload, including African Iron Overload, Iron Overload secondary to atransferrinemia and Iron Overload secondary to aceruloplasminemia, Thalassemia, Myelodysplastic Syndromes, Congenital Dyserythropoietic Anemias, Sickle Cell Disease and other Hemoglobinopathies, Red Cell Enzyme Deficiencies and Multiple Blood Transfusions.
28. A pharmaceutical composition comprising a compound as defined in claim 16, and an acceptable pharmaceutical excipient.
29. A method for treating aging or a neurodegenerative disease or disorder comprising administering a compound according to claim 16 in a subject in need thereof.
</claims>
</document>
